S Nolte1, G Liegl2, M A Petersen3, N K Aaronson4, A Costantini5, P M Fayers6, M Groenvold7, B Holzner8, C D Johnson9, G Kemmler8, K A Tomaszewski10, A Waldmann11, T E Young12, M Rose13. 1. Department of Psychosomatic Medicine, Center for Internal Medicine and Dermatology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Population Health Strategic Research Centre, School of Health and Social Development, Deakin University, Burwood, VIC, Australia. Electronic address: sandra.nolte@charite.de. 2. Department of Psychosomatic Medicine, Center for Internal Medicine and Dermatology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. 3. Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark. 4. Division of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 5. Psycho-Oncology Unit, Sant'Andrea Hospital Sapienza, University of Rome, Rome, Italy. 6. Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom. 7. Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark; Department of Public Health, University of Copenhagen, Copenhagen, Denmark. 8. Department of Psychiatry, Psychotherapy and Psychosomatics, Innsbruck Medical University, Innsbruck, Austria. 9. University of Southampton, Southampton, United Kingdom. 10. Health Outcomes Research Unit, Department of Gerontology, Geriatrics, and Social Work, Faculty of Education, Ignatianum Academy, Krakow, Poland. 11. Institute of Social Medicine and Epidemiology, University of Luebeck, Luebeck, Germany; Ministry for Health and Consumer Protection, Hamburg Cancer Registry, Hamburg, Germany. 12. East & North Hertfordshire NHS Trust Including Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom. 13. Department of Psychosomatic Medicine, Center for Internal Medicine and Dermatology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Quantitative Health Sciences, Outcomes Measurement Science, University of Massachusetts Medical School, Worcester, MA, USA.
Abstract
OBJECTIVE: The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 health-related quality of life questionnaire is one of the most widely used cancer-specific health-related quality of life questionnaires worldwide. General population norm data can facilitate the interpretation of QLQ-C30 data obtained from cancer patients. This study aimed at systematically collecting norm data from the general population to develop European QLQ-C30 norm scores and to generate comparable norm data for individual countries in Europe and North America. METHODS: We collected QLQ-C30 data from the general population across 11 European Union (EU) countries, Russia, Turkey, Canada and United States (n ≥ 1000/country). Representative samples were stratified by sex and age groups (18-39, 40-49, 50-59, 60-69 and ≥ 70 years). After applying weights based on the United Nations population distribution statistics, we calculated QLQ-C30 domain scores to generate a 'European QLQ-C30 Norm' based on the EU countries. Further, we calculated QLQ-C30 norm scores for all 15 individual countries. RESULTS: A total of 15,386 respondents completed the online survey. For the EU sample, most QLQ-C30 domains showed differences by sex/age, with men scoring somewhat better health than women, while age effects varied across domains. Substantially larger differences were seen in inter-country comparisons, with Austrian and Dutch respondents reporting consistently better health compared with British and Polish respondents. CONCLUSIONS: This study is the first to systematically collect EORTC QLQ-C30 general population norm data across Europe and North America applying a consistent data collection method across 15 countries. These new norm data facilitate valid intra-country as well as inter-country comparisons and QLQ-C30 score interpretation.
OBJECTIVE: The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 health-related quality of life questionnaire is one of the most widely used cancer-specific health-related quality of life questionnaires worldwide. General population norm data can facilitate the interpretation of QLQ-C30 data obtained from cancerpatients. This study aimed at systematically collecting norm data from the general population to develop European QLQ-C30 norm scores and to generate comparable norm data for individual countries in Europe and North America. METHODS: We collected QLQ-C30 data from the general population across 11 European Union (EU) countries, Russia, Turkey, Canada and United States (n ≥ 1000/country). Representative samples were stratified by sex and age groups (18-39, 40-49, 50-59, 60-69 and ≥ 70 years). After applying weights based on the United Nations population distribution statistics, we calculated QLQ-C30 domain scores to generate a 'European QLQ-C30 Norm' based on the EU countries. Further, we calculated QLQ-C30 norm scores for all 15 individual countries. RESULTS: A total of 15,386 respondents completed the online survey. For the EU sample, most QLQ-C30 domains showed differences by sex/age, with men scoring somewhat better health than women, while age effects varied across domains. Substantially larger differences were seen in inter-country comparisons, with Austrian and Dutch respondents reporting consistently better health compared with British and Polish respondents. CONCLUSIONS: This study is the first to systematically collect EORTC QLQ-C30 general population norm data across Europe and North America applying a consistent data collection method across 15 countries. These new norm data facilitate valid intra-country as well as inter-country comparisons and QLQ-C30 score interpretation.
Authors: Mariëtte N Verkissen; Aline De Vleminck; Mogens Groenvold; Lea J Jabbarian; Francesco Bulli; Wilfried Cools; Johannes J M van Delden; Urška Lunder; Guido Miccinesi; Sheila A Payne; Kristian Pollock; Judith A C Rietjens; Luc Deliens Journal: Support Care Cancer Date: 2021-03-19 Impact factor: 3.603
Authors: Alejandro Álvarez-Bustos; Cristina G de Pedro; María Romero-Elías; Javier Ramos; Pablo Osorio; Blanca Cantos; Constanza Maximiano; Miriam Méndez; Carmen Fiuza-Luces; Marta Méndez-Otero; Silvia Martín; Héctor Cebolla; Ana Ruiz-Casado Journal: Support Care Cancer Date: 2021-04-28 Impact factor: 3.603
Authors: Stefan Knop; Maria-Victoria Mateos; Meletios A Dimopoulos; Kenshi Suzuki; Andrzej Jakubowiak; Chantal Doyen; Paulo Lucio; Zsolt Nagy; Ganna Usenko; Ludek Pour; Mark Cook; Sebastian Grosicki; Andre Crepaldi; Anna Marina Liberati; Philip Campbell; Tatiana Shelekhova; Sung-Soo Yoon; Genadi Losava; Tomoaki Fujisaki; Mamta Garg; Jianping Wang; Susan Wroblewski; Anupa Kudva; Katharine S Gries; John Fastenau; Jesus San-Miguel; Michele Cavo Journal: BMC Cancer Date: 2021-06-02 Impact factor: 4.430